Status | Study |
Recruiting |
Study Name: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Condition: Malignant Rhabdoid Tumors (MRT) Rhabdoid Tumors of the Kidney (RTK) Date: 2015-10-21 Interventions: Drug: Tazemetostat Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine |
Recruiting |
Study Name: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Condition: Carcinoma of the Collecting Ducts of Bellini Chromophobe Renal Cell Carcinoma Date: 2013-01-10 Interventions: Drug: Pazopanib Hydrochloride Given PO Other Names: |
Completed |
Study Name: Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Condition: Renal Cell Cancer Kidney Cancer Date: 2007-04-20 Interventions: Drug: Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off. |
Active, not recruiting |
Study Name: Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Condition: Adult Acute Myeloid Leukemia in Remission Childhood Acute Lymphoblastic Leukemia in Remissio Date: 2001-12-07 Interventions: Drug: Fludarabine Phosphate Gi |